Article

Coaxial 2.2-mm microphacoemulsification reduces surgically induced astigmatism

Lisbon, Portugal - Coaxial microphacoemulsification performed through a 2.2-mm incision results in significantly less induced astigmatism than conventional coaxial phacoemulsification through a 3-mm incision, said Samuel Masket, MD, clinical professor of ophthalmology, Jules Stein Eye Institute, University of California-Los Angeles, United States.

Lisbon, Portugal - Coaxial microphacoemulsification performed through a 2.2-mm incision results in significantly less induced astigmatism than conventional coaxial phacoemulsification through a 3-mm incision, said Samuel Masket, MD, clinical professor of ophthalmology, Jules Stein Eye Institute, University of California-Los Angeles, United States.

To study whether the new small incision coaxial technique has an advantage for being more astigmatically neutral, Dr. Masket performed a comparative clinical study. Patients included had no surgical complications or corneal pathology, and all surgeries were performed through a temporally oriented clear corneal tunnel incision. The coaxial microphacoemulsification technique was done using a 1.1 mm tip and the new ultra-infusion sleeve using the Infiniti system (Alcon Laboratories). No eyes had limbal relaxing incisions and astigmatism was measured preoperatively and after 6 weeks with autokeratometry by a masked technician.

Data from a series of 32 eyes showed surgically induced astigmatism was 0.11 D for the 2.2-mm incision group compared with 0.33 D for the 3-mm incision group (p = 0.001). The axis shift was also significantly less with the smaller incision compared with the 3-mm incision, 13.4 versus 21.1° (p = 0.03). Results were similar in a second group of 16 patients who had surgery through a 2.2-mm incision in one eye and a 3-mm incision contralaterally.

“These data show a statistically significant and possibly clinically significant advantage for the smaller incision. Further studies should be directed toward investigating whether the smaller incision also has benefits for better wound stability, leakage, and risk of postoperative infection,” Dr. Masket said. He has no financial interest in Alcon Laboratories.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.